However, although an intriguing concept, implemented in the therapy of many hereditary diseases, such as cystic fibrosis and Fabry’s disease, the administration of 4-PBA can only be considered in PXE patients with mislocated ABCC6 mutants that have (partly) preserved transport activity. Here, ABCC6 is linked to Pseudoxanthoma elasticum.